Emergent BioSolutions Secures $17 Million Contract for Smallpox Antiviral TEMBEXA® Oral Suspension
Reuters
Sep 15
Emergent BioSolutions Secures $17 Million Contract for Smallpox Antiviral TEMBEXA® Oral Suspension
Emergent BioSolutions Inc. has secured a $17 million contract modification to supply TEMBEXA® (brincidofovir) oral suspension, a smallpox antiviral, through the Biomedical Advanced Research and Development Authority (BARDA). This contract is part of an ongoing 10-year agreement with the U.S. Department of Health and Human Services $(HHS)$, aimed at strengthening the U.S. supply chain for critical health countermeasures. The contract follows FDA approval for the scale-up of manufacturing this formulation, which is particularly beneficial for patients who face difficulties swallowing due to age or health conditions. Emergent's collaboration with BARDA underscores the importance of maintaining a steady supply of medical countermeasures to protect vulnerable populations in the event of a smallpox outbreak.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Emergent BioSolutions Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9528998-en) on September 15, 2025, and is solely responsible for the information contained therein.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.